Project Grant R61CA309698
- Federal Project Grant Award Summary The University of North Carolina at Chapel Hill received a $2,554,662 Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), effective March 5, 2026, through February 28, 2031. This comprehensive research initiative focuses on developing biomaterial-enhanced Chimeric Antigen Receptor (CAR) T-cell and Natural Killer T (NKT) cell therapies to improve treatment outcomes for glioblastoma, a highly...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of North Carolina at Chapel Hill a Project Grant totaling $624,194 under the Cancer Biology Research program (CFDA 93.396) effective April 1, 2026 through March 31, 2031. This five-year award supports fundamental research investigating how the integrated stress response (ISR) regulates CD8+ tumor-infiltrating lymphocyte (TIL) function and immunometabolism within the tumor microenvironment (TME). The research...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of North Carolina at Chapel Hill a Project Grant of $627,676 under the Cancer Biology Research program (CFDA 93.396) for the period September 1, 2025 through August 31, 2028. This three-year research initiative focuses on developing and validating genetically-encoded biosensors to characterize intercellular heterogeneity in cell cycle quiescence—specifically the spectrum of quiescent (dormant) states in cancer...
- Federal Project Grant Award Summary The University of North Carolina at Chapel Hill received a $197,747 Project Grant awarded on August 6, 2025, by the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398). The I-ACCESS (Improving Affordability in Cancer Care Through Economic Screening and Support) initiative will develop and pilot a screening assessment and referral program designed to proactively identify cancer-related financial hardship in patients across diverse...
- Federal Project Grant Award Summary The University of North Carolina at Chapel Hill received a $2,257,345 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) for the period September 1, 2025 through August 31, 2029. The award supports the development of next-generation microscopy instrumentation and computational methods to advance biological research across spatiotemporal scales. The project will...
- Federal Grant Award Summary The University of Chicago received a $372,628 Project Grant from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) effective September 12, 2025, through August 31, 2028. This award supports the development and advancement of spatiomolecular profiling technologies for cancer research, specifically building upon the institution's Array-Seq large-format spatially resolved transcriptomics (ST) platform. The project...
- Federal Grant Award Summary Duke University's Office of Research Administration received a $415,257 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective July 3, 2025, with completion targeted for June 30, 2027. This research initiative focuses on developing novel chimeric antigen receptor (CAR) T-cell therapies by harnessing B cells from patients following stem cell transplantation for hematological malignancies...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $584,510 to the University of Colorado-Denver on September 12, 2025, under the Cancer Biology Research program (CFDA 93.396) to support the development and implementation of advanced spatial transcriptomics and proteomics technologies for studying tumor microenvironments. Through the Human Immune Monitoring Shared Resource (HIMSR) at the University of Colorado Cancer Center, this funding supports a...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $223,176 Project Grant under the Cancer Research Manpower program (CFDA 93.398) to Duke University on September 10, 2025, with a completion date of April 30, 2028. This F32 postdoctoral fellowship award supports research investigating the role of SMARCAL1 (an annealing helicase) depletion in enhancing immunogenicity within Alternative Lengthening of Telomeres (ALT)-positive high-grade gliomas. The research addresses a...
- Federal Grant Award Summary The National Cancer Institute awarded the University of Illinois a $386,279 Project Grant on July 10, 2025, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop innovative immunotherapy screening capabilities. The grant funds the creation of a microfluidic device cassette and associated functional immune assay protocols designed to enable personalized immunotherapy screening directly on core needle biopsies from cancer patients. This...
The University of North Carolina at Chapel Hill received a $207,802 Project Grant award from the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394) for the period May 1, 2026 through April 30, 2029. The award supports the development of multiplexed multiscale imaging technologies and automated analysis systems designed to advance cellular immunotherapy research. Specifically, the project will develop novel fluorescent probes capable of simultaneously visualizing multiple proteins in immune cells, tumor cells, and immune synapses at resolutions ranging from one micron to tens of nanometers. This advancement addresses critical limitations in current flow cytometry and cytotoxicity assays used in cellular immunotherapy research and development. In parallel, the project will develop computer vision and machine learning-enabled automated microscopy systems capable of capturing population-level statistics about immune and tumor cell interactions while simultaneously acquiring high-resolution structural information about immune synapse formation and organization. These integrated technologies are intended to provide researchers with detailed insights into how synthetic receptors organize and regulate synapse formation—a critical factor in developing and evaluating effective cellular immunotherapy treatments that reprogram a patient's own immune cells to recognize and destroy tumor cells, particularly in hematopoietic malignancies and solid tumors.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $207.8k | 4/9/26 |